Intersect Ent: peers
Intersect Ent beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Intersect Ent, CeriBell, Inc., AdaptHealth Corp.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Intersect Entbase XENT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Integra LifeSciences Holdings Corporation IART · 🇺🇸 US Percentile in Healthcare Percentile in USA | CeriBell, Inc. CBLL · 🇺🇸 US Percentile in Healthcare Percentile in USA | SI-BONE, Inc. SIBN · 🇺🇸 US Percentile in Healthcare Percentile in USA | AdaptHealth Corp. AHCO · 🇺🇸 US Percentile in Healthcare Percentile in USA | IRadimed Corporation IRMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Varex Imaging Corporation VREX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Cytek Biosciences, Inc. CTKB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $914 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one4th of 8 | $921 MOct 22, 2026 · Market data3rd of 8 | $895 MAug 1, 2026 · Market data5th of 8 | $1.0 BOct 30, 2026 · Market data2nd of 8 | $792 MAug 1, 2026 · Market data6th of 8 | $1.1 BSep 25, 2026 · Market data1st of 8 | $778 MOct 16, 2026 · Market data7th of 8 | $770 MOct 27, 2026 · Market data8th of 8 | $905 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $107 MFY2021 · SEC6th of 8 | $1.6 BFY2025 · SEC2nd of 8 | $89 MFY2025 · SEC7th of 8 | $201 MFY2025 · SEC5th of 8 | $3.2 BFY2025 · SEC1st of 8 | $84 MFY2025 · SEC8th of 8 | $845 MFY2025 · SEC3rd of 8 | $201 MFY2025 · SEC4th of 8 | $201 M8 ranked |
| Net income (Higher is better) | $-160 MFY2021 · SEC7th of 8 | $-516 MFY2025 · SEC8th of 8 | $-53 MFY2025 · SEC3rd of 8 | $-19 MFY2025 · SEC2nd of 8 | $-71 MFY2025 · SEC6th of 8 | $22 MFY2025 · SEC1st of 8 | $-70 MFY2025 · SEC5th of 8 | $-67 MFY2025 · SEC4th of 8 | $-68 M8 ranked |
| Employees (Better neither way: ranked highest first) | 406As on December 2020 · Profile4th of 8 | 3,800As on December 2021 · Profile2nd of 8 | 327December 31, 2025 · Profile7th of 8 | 357As on 2022 · Profile6th of 8 | 10,700As on 2021 · Profile1st of 8 | 166December 31, 2025 · Profile8th of 8 | 2,100As on 2021 · Profile3rd of 8 | 390As on March 2021 · Profile5th of 8 | 3988 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | —— | —— | +11.1%30 days to Oct 27, 2026 · Market dataonly one with it | +11.1%— |
| Revenue growth (Higher is better) | ———— | +1.5%FY2025 · SEC5th of 730th34th | +36.1%FY2025 · SEC1st of 780th88th | +20.2%FY2025 · SEC2nd of 769th79th | -0.5%FY2025 · SEC7th of 725th28th | +14.4%FY2025 · SEC3rd of 758th71st | +4.1%FY2025 · SEC4th of 735th42nd | +0.5%FY2025 · SEC6th of 727th30th | +4.1%7 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +1.6%FY2025 · SEC5th of 631st39th | ———— | +23.6%FY2025 · SEC1st of 676th88th | +3.0%FY2025 · SEC4th of 637th44th | +16.3%FY2025 · SEC2nd of 667th81st | -0.6%FY2025 · SEC6th of 626th31st | +7.1%FY2025 · SEC3rd of 647th60th | +5.0%6 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | +16.7%FY2025 · SEConly one with it59th59th | ———— | ———— | +16.7%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 50.9%FY2025 · SEC5th of 738th65th | 87.9%FY2025 · SEC1st of 789th96th | 79.6%FY2025 · SEC2nd of 780th91st | 18.8%FY2025 · SEC7th of 78th18th | 76.8%FY2025 · SEC3rd of 777th88th | 34.4%FY2025 · SEC6th of 720th42nd | 51.8%FY2025 · SEC4th of 739th66th | 51.8%7 ranked |
| Operating margin (Higher is better) | ———— | -30.2%FY2025 · SEC6th of 738th19th | -65.6%FY2025 · SEC7th of 728th13th | -11.1%FY2025 · SEC4th of 747th26th | 2.8%FY2025 · SEC2nd of 762nd48th | 31.2%FY2025 · SEC1st of 795th94th | -3.3%FY2025 · SEC3rd of 753rd34th | -20.0%FY2025 · SEC5th of 741st22nd | -11.1%7 ranked |
| Net margin (Higher is better) | ———— | -31.6%FY2025 · SEC5th of 737th18th | -60.0%FY2025 · SEC7th of 729th13th | -9.4%FY2025 · SEC4th of 748th28th | -2.2%FY2025 · SEC2nd of 757th38th | 26.8%FY2025 · SEC1st of 792nd93rd | -8.3%FY2025 · SEC3rd of 750th29th | -33.0%FY2025 · SEC6th of 736th17th | -9.4%7 ranked |
| Free cash flow margin (Higher is better) | ———— | -1.9%FY2025 · SEC4th of 749th30th | -46.7%FY2025 · SEC7th of 728th12th | -4.5%FY2025 · SEC6th of 745th26th | 6.8%FY2025 · SEC2nd of 766th60th | 20.5%FY2025 · SEC1st of 788th89th | 2.2%FY2025 · SEC3rd of 757th42nd | -4.3%FY2025 · SEC5th of 745th26th | -1.9%7 ranked |
| Return on equity (Higher is better) | ———— | -39.9%FY2025 · SEC7th of 749th21st | -30.8%FY2025 · SEC6th of 753rd23rd | -11.0%FY2025 · SEC3rd of 766th33rd | -4.6%FY2025 · SEC2nd of 770th37th | 24.8%FY2025 · SEC1st of 793rd89th | -14.0%FY2025 · SEC4th of 764th30th | -18.1%FY2025 · SEC5th of 761st29th | -14.0%7 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 70.9×price Oct 22, 2026 · Market data1st of 382nd92nd | ———— | ———— | ———— | 45.4×price Sep 25, 2026 · Market data2nd of 368th85th | 35.2×price Oct 16, 2026 · Market data3rd of 356th78th | ———— | 45.4×3 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | 0.6×price Oct 22, 2026 · Market data5th of 510th17th | 8.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.6×price Oct 30, 2026 · Market data2nd of 555th75th | 0.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 12.2×price Sep 25, 2026 · Market data1st of 577th91st | 0.9×price Oct 16, 2026 · Market data4th of 515th27th | 3.7×price Oct 27, 2026 · Market data3rd of 550th69th | 3.7×5 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 0.9×price Oct 22, 2026 · Market data5th of 516th17th | 5.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 5.7×price Oct 30, 2026 · Market data2nd of 571st79th | 0.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 11.5×price Sep 25, 2026 · Market data1st of 586th91st | 1.6×price Oct 16, 2026 · Market data4th of 533rd40th | 2.3×price Oct 27, 2026 · Market data3rd of 540th52nd | 2.3×5 ranked |
| Free cash flow yield (Higher is better) | ———— | -3.4%price Oct 22, 2026 · Market data5th of 557th29th | -4.7%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -0.9%price Oct 30, 2026 · Market data3rd of 565th35th | 27.7%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 1.6%price Sep 25, 2026 · Market data2nd of 574th44th | 2.4%price Oct 16, 2026 · Market data1st of 577th49th | -1.1%price Oct 27, 2026 · Market data4th of 564th34th | -0.9%5 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.7×FY2025 · SEC2nd of 464th55th | ———— | 0.2×FY2025 · SEC1st of 432nd23rd | 1.1×FY2025 · SEC4th of 478th71st | ———— | 0.8×FY2025 · SEC3rd of 468th60th | ———— | 0.7×4 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | 3.5×FY2025 · SEConly one with it74th68th | ———— | ———— | ———— | 3.5×— |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | 0.9×FY2025 · SEConly one with it74th52nd | ———— | ———— | ———— | 0.9×— |
| Piotroski F-score (Higher is better) | —— | 5 of 9FY2025 · SEC2nd of 4 | —— | 6 of 9FY2025 · SEC1st of 4 | 4 of 9FY2025 · SEC4th of 4 | —— | 5 of 9FY2025 · SEC2nd of 4 | —— | 5.0 of 94 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 8 of 24FY2025 · Scorecard4th of 7 | 3 of 9FY2025 · Scorecard4th of 7 | 10 of 24FY2025 · Scorecard3rd of 7 | 6 of 18FY2025 · Scorecard4th of 7 | 18 of 25FY2025 · Scorecard1st of 7 | 10 of 22FY2025 · Scorecard2nd of 7 | 7 of 22FY2025 · Scorecard7th of 7 | 33% passed7 ranked |
| Valuation checks (Higher is better) | —— | 2 of 6FY2025 · Scorecard1st of 5 | —— | 0 of 5FY2025 · Scorecard4th of 5 | —— | 0 of 6FY2025 · Scorecard4th of 5 | 2 of 6FY2025 · Scorecard1st of 5 | 1 of 6FY2025 · Scorecard3rd of 5 | 17% passed5 ranked |
| Growth checks (Higher is better) | —— | 2 of 6FY2025 · Scorecard5th of 7 | 1 of 2FY2025 · Scorecard4th of 7 | 5 of 6FY2025 · Scorecard2nd of 7 | 2 of 6FY2025 · Scorecard5th of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 2 of 6FY2025 · Scorecard5th of 7 | 3 of 5FY2025 · Scorecard3rd of 7 | 50% passed7 ranked |
| Profitability checks (Higher is better) | —— | 0 of 5FY2025 · Scorecard5th of 7 | 0 of 3FY2025 · Scorecard5th of 7 | 1 of 5FY2025 · Scorecard2nd of 7 | 1 of 5FY2025 · Scorecard2nd of 7 | 5 of 5FY2025 · Scorecard1st of 7 | 1 of 5FY2025 · Scorecard2nd of 7 | 0 of 5FY2025 · Scorecard5th of 7 | 20% passed7 ranked |
| Financial health checks (Higher is better) | —— | 3 of 4FY2025 · Scorecard4th of 7 | 2 of 3FY2025 · Scorecard5th of 7 | 4 of 5FY2025 · Scorecard3rd of 7 | 2 of 6FY2025 · Scorecard7th of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 4 of 4FY2025 · Scorecard1st of 7 | 2 of 3FY2025 · Scorecard5th of 7 | 75% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | 1 of 3FY2025 · Scorecard4th of 7 | 0 of 1FY2025 · Scorecard6th of 7 | 0 of 3FY2025 · Scorecard6th of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 4 of 5FY2025 · Scorecard3rd of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 33% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 95.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 81.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 107.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 104.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 61.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 92.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 66.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 92.5%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 2342026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 1332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 1792026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 2482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 2152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 1802026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 1522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 1807 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | -1.7 pp2026-Q2 against 2026-Q1 · 13F5th of 7 | +0.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 7 | +9.7 pp2026-Q2 against 2026-Q1 · 13F1st of 7 | -0.1 pp2026-Q2 against 2026-Q1 · 13F4th of 7 | +1.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 7 | -2.0 pp2026-Q2 against 2026-Q1 · 13F6th of 7 | -3.1 pp2026-Q2 against 2026-Q1 · 13F7th of 7 | -0.1 pp7 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | 1.4%FY2025 · SEConly one with it63rd35th | ———— | ———— | 1.4%— |
| Shareholder yield (Higher is better) | ———— | 0.0%FY2025 · SEC3rd of 314th6th | ———— | ———— | 0.0%†FY2025 · SECnot ranked: old priceold priceold price | 1.4%FY2025 · SEC2nd of 339th26th | ———— | 2.0%FY2025 · SEC1st of 348th34th | 1.4%3 ranked |
| Dividend payout (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | 66.9%FY2025 · SEConly one with it84th74th | ———— | ———— | 66.9%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | $0.00FY2025 · SEConly one with it | —— | —— | —— | —— | $0.00— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Intersect Ent: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Integra LifeSciences Holdings Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CeriBell, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; SI-BONE, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AdaptHealth Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; IRadimed Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Varex Imaging Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cytek Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Intersect Ent | — | — | — |
| Integra LifeSciences Holdings Corporation | -30.2%FY2025 | 38th percentile in Healthcaremedian -7.7%, 674 companies | 19th percentile in USAmedian 3.5%, 2,594 companies |
| CeriBell, Inc. | -65.6%FY2025 | 28th percentile in Healthcaremedian -7.7%, 674 companies | 13th percentile in USAmedian 3.5%, 2,594 companies |
| SI-BONE, Inc. | -11.1%FY2025 | 47th percentile in Healthcaremedian -7.7%, 674 companies | 26th percentile in USAmedian 3.5%, 2,594 companies |
| AdaptHealth Corp. | 2.8%FY2025 | 62nd percentile in Healthcaremedian -7.7%, 674 companies | 48th percentile in USAmedian 3.5%, 2,594 companies |
| IRadimed Corporation | 31.2%FY2025 | 95th percentile in Healthcaremedian -7.7%, 674 companies | 94th percentile in USAmedian 3.5%, 2,594 companies |
| Varex Imaging Corporation | -3.3%FY2025 | 53rd percentile in Healthcaremedian -7.7%, 674 companies | 34th percentile in USAmedian 3.5%, 2,594 companies |
| Cytek Biosciences, Inc. | -20.0%FY2025 | 41st percentile in Healthcaremedian -7.7%, 674 companies | 22nd percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Intersect Ent | Integra LifeSciences Holdings Corporation | CeriBell, Inc. | SI-BONE, Inc. | AdaptHealth Corp. | IRadimed Corporation | Varex Imaging Corporation | Cytek Biosciences, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $1.6 BSEC2nd | $89 MSEC6th | $201 MSEC5th | $3.2 BSEC1st | $84 MSEC7th | $845 MSEC3rd | $201 MSEC4th |
| 2024 | — | $1.6 BSEC2nd | $65 MSEC7th | $167 MSEC5th | $3.3 BSEC1st | $73 MSEC6th | $811 MSEC3rd | $200 MSEC4th |
| 2023 | — | $1.5 BSEC2nd | $45 MSEC7th | $139 MSEC5th | $3.2 BSEC1st | $66 MSEC6th | $893 MSEC3rd | $193 MSEC4th |
| 2022 | — | $1.6 BSEC2nd | — | $106 MSEC5th | $3.0 BSEC1st | $53 MSEC6th | $859 MSEC3rd | $164 MSEC4th |
| 2021 | $107 MSEC5th | $1.5 BSEC2nd | — | $90 MSEC6th | $2.5 BSEC1st | $42 MSEC7th | $818 MSEC3rd | $128 MSEC4th |
| 2020 | $81 MSEC5th | $1.4 BSEC1st | — | $73 MSEC6th | $1.1 BSEC2nd | $32 MSEC7th | $738 MSEC3rd | $93 MSEC4th |
| 2019 | $109 MSEC4th | $1.5 BSEC1st | — | $67 MSEC5th | $530 MSEC3rd | $39 MSEC6th | $781 MSEC2nd | — |
| 2018 | $108 MSEC4th | $1.5 BSEC1st | — | $55 MSEC5th | $345 MSEC3rd | $30 MSEC6th | $773 MSEC2nd | — |
| 2017 | $96 MSEC3rd | $1.2 BSEC1st | — | $48 MSEC4th | — | $23 MSEC5th | $698 MSEC2nd | — |
| 2016 | $79 MSEC3rd | $992 MSEC1st | — | — | — | $33 MSEC4th | $620 MSEC2nd | — |
| 2015 | $62 MSEC3rd | $883 MSEC1st | — | — | — | $32 MSEC4th | $632 MSEC2nd | — |
| 2014 | $39 MSEC2nd | $797 MSEC1st | — | — | — | $16 MSEC3rd | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Intersect Ent#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Integra LifeSciences Holdings CorporationIART · 🇺🇸 USASame industry: Medical Devices · Similar size: $921 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $921 M (Oct 22, 2026) · revenue $1.6 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- CeriBell, Inc.CBLL · 🇺🇸 USASame industry: Medical Devices · Similar size: $895 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $895 M (Aug 1, 2026) · revenue $89 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- SI-BONE, Inc.SIBN · 🇺🇸 USASame industry: Medical Devices · Similar size: $1.0 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.0 B (Oct 30, 2026) · revenue $201 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- AdaptHealth Corp.AHCO · 🇺🇸 USASame industry: Medical Devices · Similar size: $792 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $792 M (Aug 1, 2026) · revenue $3.2 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- IRadimed CorporationIRMD · 🇺🇸 USASame industry: Medical Devices · Similar size: $1.1 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.1 B (Sep 25, 2026) · revenue $84 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Varex Imaging CorporationVREX · 🇺🇸 USASame industry: Medical Devices · Similar size: $778 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $778 M (Oct 16, 2026) · revenue $845 M (year to October 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Cytek Biosciences, Inc.CTKB · 🇺🇸 USASame industry: Medical Devices · Similar size: $770 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $770 M (Oct 27, 2026) · revenue $201 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Artivion, Inc.AORT · 🇺🇸 USASame industry: Medical Devices · Similar size: $739 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $739 M (Oct 30, 2026) · revenue $441 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Avanos Medical, Inc.AVNS · 🇺🇸 USASame industry: Medical Devices · Similar size: $1.2 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.2 B (last known, Aug 1, 2026) · revenue $701 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- MiMedx Group, Inc.MDXG · 🇺🇸 USASame industry: Medical Devices · Similar size: $684 M market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $684 M (Oct 14, 2026) · revenue $419 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- CONMED CorporationCNMD · 🇺🇸 USASame industry: Medical Devices · Similar size: $1.4 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.4 B (Oct 14, 2026) · revenue $1.4 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Tandem Diabetes Care, Inc.TNDM · 🇺🇸 USASame industry: Medical Devices · Similar size: $1.4 B market cap against $914 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.4 B (Oct 30, 2026) · revenue $1.0 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.